



Thor Medical's AlphaOne Facility to be Officially Opened by Norwegian Prime Minister Jonas Gahr Støre

19.8.2026 07:00:00 CEST | Thor Medical ASA | Non-regulatory press releases

Thor Medical, a leading supplier of high-purity isotopes to the radiopharmaceutical industry, today announced that its AlphaOne production facility at Herøya Industrial Park will be officially opened by Norwegian Prime Minister Jonas Gahr Støre on September 9, 2026.

AlphaOne is Thor Medical's first industrial-scale production facility for high-purity alpha-emitting radioisotopes and the first facility of its kind in the world. The facility is already in operation, producing isotopes for use in next-generation targeted cancer therapies.

"We are pleased to welcome Prime Minister Jonas Gahr Støre to AlphaOne. The facility represents an important step in building a reliable and scalable supply of high-purity alpha emitters for the radiopharmaceutical industry, and we look forward to marking this milestone together with our employees, partners and guests," said Jasper Kurth, CEO of Thor Medical.

The opening ceremony is an invitation-only event. Members of the media wishing to attend are asked to contact Mathias Nilsen Reiherth at mathias.reiherth@thormedical.com for accreditation by September 7.

Contacts

- Mathias Nilsen Reiherth, Head of Communications and Corporate Affairs, +47 988 05 724, mathias.reiherth@thormedical.com

About Thor Medical ASA

ABOUT THOR MEDICAL ASA

Thor Medical is a leading supplier of high-purity isotopes to the radiopharmaceutical industry. The Company's proprietary production platform combines advanced separation technology with industrial-scale manufacturing capacity to deliver a reliable, scalable and cost-efficient supply of alpha-emitting radioisotopes. Thor Medical supports radiopharmaceutical companies from early-stage development to commercialization enabling scale-up of next-generation targeted cancer therapies.

Thor Medical's product portfolio includes lead-212 (Pb-212) and its precursor isotopes thorium-228 (Th-228) and radium-224 (Ra-224). Based on naturally occurring thorium, Thor Medical's production process requires neither irradiation nor nuclear reactors, providing significant cost advantages while minimizing radioactive waste.

Guided by its vision to become a world-leading enabler for targeted cancer therapies, Thor Medical is committed to improving millions of lives by powering the next generation of precision cancer treatment with high-purity isotopes.

Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the ticker symbol TRMED. For more information, visit www.thormedical.com.

Attachments

- [Download announcement as PDF.pdf](#)